PMID- 25683226
OWN - NLM
STAT- MEDLINE
DCOM- 20150707
LR  - 20181113
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Print)
IS  - 1545-5009 (Linking)
VI  - 62
IP  - 5
DP  - 2015 May
TI  - Dermatologic adverse events in pediatric patients receiving targeted anticancer 
      therapies: a pooled analysis.
PG  - 798-806
LID - 10.1002/pbc.25429 [doi]
AB  - BACKGROUND: The dermatologic adverse events (AEs) of various molecularly targeted 
      therapies are well-described in adult cancer patients. Little has been reported 
      on the incidence and clinical presentation of such AEs in pediatric patients with 
      cancer. To address this gap, we analyzed the dermatologic AEs reported across 
      clinical trials of targeted anticancer therapies in pediatric patients. 
      PROCEDURES: We conducted an electronic literature search (PubMed, American 
      Society of Clinical Oncology annual meetings' abstracts, ClinicalTrials.gov, 
      NCI's Pediatric Oncology Branch webpage) to identify clinical trials involving 
      targeted anticancer therapies that reported dermatologic AEs in their safety 
      data. Studies were limited to the pediatric population, monotherapy trials 
      (oncology), and English language publications. RESULTS: Pooled data from 19 
      clinical studies investigating 11 targeted anticancer agents (alemtuzumab, 
      rituximab, imatinib, dasatinib, erlotinib, vandetanib, sorafenib, cabozantinib, 
      pazopanib, everolimus, and temsirolimus) were analyzed. The most frequently 
      encountered dermatologic AEs were rash (127/660; 19%), xerosis (18/100; 18%), 
      mucositis (68/402; 17%), and pruritus (12/169; 7%). Other AEs included pigmentary 
      abnormalities of the skin/hair (13%), hair disorders (trichomegaly, 
      hypertrichosis, alopecia, and madarosis; 14%), urticaria (7%), palmoplantar 
      erythrodysesthesia (7%), erythema, acne, purpura, skin fissures, other 'unknown 
      skin changes', exanthem, infection, flushing, telangiectasia, and 
      photosensitivity. CONCLUSION: This study describes the dermatologic 
      manifestations of targeted anticancer therapy-related AEs in the pediatric 
      population. Since these AEs are often associated with significant morbidity, it 
      is imperative that pediatric oncologists be familiar with their recognition and 
      management, to avoid unnecessary dose modifications and/or termination, and to 
      prevent impairments in patients' quality of life.
CI  - (c) 2015 Wiley Periodicals, Inc.
FAU - Belum, Viswanath Reddy
AU  - Belum VR
AD  - Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY 
      USA.
FAU - Washington, Courtney
AU  - Washington C
AD  - Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY 
      USA.
AD  - Philadelphia College of Osteopathic Medicine, Suwanee, GA, USA.
FAU - Pratilas, Christine A
AU  - Pratilas CA
AD  - Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 
      USA.
FAU - Sibaud, Vincent
AU  - Sibaud V
AD  - Department of Dermatology, Institut Claudius Regaud, Institut Universitaire 
      Cancer Toulouse-oncopole, Toulouse, France.
FAU - Boralevi, Franck
AU  - Boralevi F
AD  - Unite de Dermatologie Pediatrique, Hopital Pellegrin-enfants, Place Amelie 
      Raba-Leon, 33076 Bordeaux Cedex, France.
FAU - Lacouture, Mario E
AU  - Lacouture ME
AD  - Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY 
      USA.
LA  - eng
GR  - R25 CA020449/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20150212
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/*adverse effects
MH  - Child
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Molecular Targeted Therapy/*adverse effects
MH  - Neoplasms/*drug therapy/pathology
MH  - Prognosis
MH  - Skin Diseases/*chemically induced/pathology
PMC - PMC4376610
MID - NIHMS651866
OTO - NOTNLM
OT  - adverse events
OT  - dermatologic
OT  - mucositis
OT  - pediatric
OT  - pruritus
OT  - rash
OT  - targeted therapies
EDAT- 2015/02/17 06:00
MHDA- 2015/07/08 06:00
PMCR- 2016/05/01
CRDT- 2015/02/17 06:00
PHST- 2014/09/17 00:00 [received]
PHST- 2014/12/18 00:00 [revised]
PHST- 2014/12/19 00:00 [accepted]
PHST- 2015/02/17 06:00 [entrez]
PHST- 2015/02/17 06:00 [pubmed]
PHST- 2015/07/08 06:00 [medline]
PHST- 2016/05/01 00:00 [pmc-release]
AID - 10.1002/pbc.25429 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2015 May;62(5):798-806. doi: 10.1002/pbc.25429. Epub 2015 
      Feb 12.